Integral BioSystems to Exhibit at Drug Development Outsourcing Conference Sept. 24 in New Jersey

Integral BioSystems will exhibit at Table 41 at the Drug Development Contracting & Outsourcing Conference on Sept. 24, 2026, at the Hyatt Regency in New Brunswick, New Jersey. CEO and President Dr. Shikha P. Barman will be available to discuss formulation development, scale-up and drug delivery strategies with attendees.

Why it matters: - The conference gives drug developers a chance to meet a contract research organization that focuses on formulation and delivery challenges across small and large molecule programs. - Integral BioSystems is positioning its services for companies looking to move candidates from development into CMC, scale-up and technology transfer. - The event can be especially relevant for teams working on ophthalmic, injectable, intranasal, pulmonary, dermal and other specialized dosage forms.

What happened: - Integral BioSystems will exhibit at Table #41 on Sept. 24, 2026, at the Hyatt Regency Hotel in New Brunswick, New Jersey. - The company said CEO and President Dr. Shikha P. Barman will be on hand to meet interested attendees and discuss their project requirements. - The event is the Drug Development Contracting & Outsourcing Conference.

The details: - Integral BioSystems operates from a 10,000-square-foot facility in Bedford, Massachusetts. - The company focuses on formulation and analytical method development, stability assessments, bioanalytics and scale-up/technology transfer. - Its development experience includes biodegradable microspheres and nanospheres, drug suspensions, generics, 505(b)(1), OTC and 505(b)(2) products, small molecules, proteins and biosimilars, nucleic acid formulations including DNA and RNAi, and vaccines. - Delivery routes include injectables, ophthalmics, intranasals, otic, pulmonary and dermal. - The company offers R&D and cGLP services, R&D and cGLP stability studies, toxicology supplies, process development, scale-up and technology transfer. - Integral BioSystems says it has more than 28 years of experience in cell- and tissue-targeted, sustained-release pharmaceutical formulation development. - The company describes itself as a specialty drug delivery contract research organization with an integrated approach to formulation development for small and large molecule drug candidates. - Integral BioSystems also partners with pharmaceutical companies to co-develop products using its proprietary pharmaceutical delivery systems. - The company has developed numerous dosage forms for ophthalmic applications. - Integral BioSystems customizes dosage forms for sustained release, targeted tissue-focused delivery or fast-release and instant delivery, depending on the product goal. - Dr. Barman will also be available to answer questions from companies developing a new drug substance, a 505(b)(2) product or a generic drug product.

Between the lines: - The booth appearance is a direct business-development play aimed at connecting with sponsors that need formulation, development and outsourcing support. - The emphasis on multiple dosage forms and delivery routes signals a broad technical platform rather than a single-asset focus. - The company is leaning on Dr. Barman's long experience as a differentiator in a crowded outsourcing market.

What's next: - Attendees can meet the Integral BioSystems team at Table #41 during the Sept. 24 conference. - Prospective clients can use the event to discuss formulation strategy, development timelines and delivery-system options for their programs. - More information is available in the company's announcement: the company's announcement

The bottom line: - Integral BioSystems is using the New Brunswick conference to showcase its drug delivery and formulation development capabilities to potential partners and clients.